BTIG analyst Julian Harrison raised the firm’s price target on CymaBay Therapeutics to $18 from $15 and keeps a Buy rating on the shares. The ELATIVE trial results from Ipsen and Genfit leave a good chance for CymaBay’s seladelpar to emerge as the best-in-class PPAR agonist for primary biliary cholangitis, the analyst tells investors in a research note. The firm views the results as the “best case scenario” for CymaBay.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CBAY:
